EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Immunome, Inc.
IMNM

IMNM Immunome, Inc.

Immunome, Inc. · NASDAQ
Market Closed
24.67
▼ ⁦-1.20%⁩ (-0.30)
Market Cap$2.4B
Beta2.12
52w Low52w High
8.6630.06
Last Week
⁦-9.73%⁩
Last Month
⁦-3.97%⁩
Last 3 Months
⁦+11.58%⁩
Last Year
⁦+148.69%⁩
EL7 Factor Analysis
How we score this
Overall9
Poor — bottom quartile of the marketMomentum TrapF 3/9SafeBetter than 9% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
20
—17.8xBottom tier
▸
Growth
13
-100.0%▼7.1%Bottom tier
▸
Quality
7
-67.0%▼4.5%Bottom tier
▸
Safety
70
—2.6xTop tier
▸
Capital Return
45
—2.12%Around median
▸
Momentum
78
143.0%▲2.9%Top tier
▸
Sentiment
39
9▲3Bottom tier

Frequently Asked Questions

What is Immunome, Inc. stock?▼

Immunome, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Immunome, Inc.?▼

You can buy Immunome, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Immunome, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Immunome, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Immunome, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Current price$25
Analyst target · 5 analysts
$36
⁦+44%⁩
See it clearly undervalued
Range ⁦$33–$37⁩
vs
DCF (estimate)
N/A (negative FCF)

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 5 analysts setting price target
$35.25
⁦+42.9%⁩
Current Price $24.67·Median $35.50
Low
$33.00
High
$37.00
Current price
$24.67
Average target
$35.25
Street summary

Immunome’s Price Targets Remain Stable Amid Diverging Future Outlook

Price target expectations have not changed over the last 30 days; consensus remained at $35.25 with five analysts, while the range was between $33 and $37, reflecting limited dispersion around an average estimate above the current price of $24.67. The latest rating updates also recorded no change in ratings, with H.C. Wainwright maintaining «Buy» on September 11, while Wedbush had previously maintained «Outperform».

As of 2026-09-11
Revisions momentum · 30d
⁦0.0%⁩
Average rating
★ 4.21
Buy
Analyst coverage
14
Buy conviction
100%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
16%
Analyst ratings over time14 analysts rating
3
11
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.20 → 4.21
Recent analyst moves
  • = Reiterate2026-09-11
    H.C. Wainwright
    Buy
  • = Reiterate2026-08-12
    Wedbush
    Outperform
  • = Reiterate2026-07-09
    H.C. Wainwright
    Buy
Premium content
Financial Analysis
|